Literature DB >> 28602505

Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice.

D Fabregat-Safont1, M Barneo-Muñoz2, F Martinez-Garcia2, J V Sancho1, F Hernández1, M Ibáñez3.   

Abstract

New psychoactive substances (NPS) are a new breed of synthetically produced substances designed to mimic the effects of traditional illegal drugs. Synthetic cannabinoids and synthetic cathinones are the two most common groups, which try to mimic the effects of the natural compounds 9Δ-tetrahydrocannabinol and cathinone, respectively. Similarly, synthetic tryptamines are designer compounds which are based on the compounds psilocin, N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine found in some mushrooms. One of the most important tryptamine compounds found in seizures is 5-methoxy-N,N-diisopropyltryptamine, which has been placed as controlled substance in USA and some European countries. The control of this compound has promoted the rising of another tryptamine, the 5-methoxy-N-methyl-N-isopropyltryptamine, which at the time of writing this article has not been banned yet. So, it is undeniable that this new substance should be monitored. 5-methoxy-N-methyl-N-isopropyltryptamine has been reported by the Spanish Early Warning System and detected in our laboratory in two pill samples purchased in a local smart shop. This has promoted the need of stablishing consumption markers for this compound in consumers' urine. In the present work, the metabolism and pharmacokinetic of 5-methoxy-N-methyl-N-isopropyltryptamine has been studied by an in vivo approach, using adult male mice of the inbred strain C57BLJ/6. The use of ultra-high performance liquid chromatography coupled to high resolution mass spectrometry allowed the identification of four metabolites. After the pharmacokinetic study in serum and urine, the O-demethylated metabolite and the non-metabolised parent compound are proposed as consumption markers in hydrolysed urine. Data reported in this work will help hospitals and forensic laboratories to monitor the consumption and potential intoxication cases related to this tryptamine.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-MeO-MiPT; High resolution mass spectrometry; In vivo studies; Metabolite identification; New psychoactive substances; Tryptamines

Mesh:

Substances:

Year:  2017        PMID: 28602505     DOI: 10.1016/j.chroma.2017.06.010

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  5 in total

Review 1.  Toxicology and Analysis of Psychoactive Tryptamines.

Authors:  Sara Malaca; Alfredo Fabrizio Lo Faro; Alice Tamborra; Simona Pichini; Francesco Paolo Busardò; Marilyn A Huestis
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

2.  Metabolism study and toxicological determination of mephtetramine in biological samples by liquid chromatography coupled with high-resolution mass spectrometry.

Authors:  Sara Odoardi; Serena Mestria; Giulia Biosa; Raffaella Arfè; Micaela Tirri; Matteo Marti; Sabina Strano Rossi
Journal:  Drug Test Anal       Date:  2021-05-04       Impact factor: 3.234

3.  In-depth comparison of the metabolic and pharmacokinetic behaviour of the structurally related synthetic cannabinoids AMB-FUBINACA and AMB-CHMICA in rats.

Authors:  David Fabregat-Safont; María Mata-Pesquera; Manuela Barneo-Muñoz; Ferran Martinez-Garcia; Marie Mardal; Anders B Davidsen; Juan V Sancho; Félix Hernández; María Ibáñez
Journal:  Commun Biol       Date:  2022-02-24

4.  Human Hepatocyte 4-Acetoxy-N,N-Diisopropyltryptamine Metabolite Profiling by Reversed-Phase Liquid Chromatography Coupled with High-Resolution Tandem Mass Spectrometry.

Authors:  Sara Malaca; Marilyn A Huestis; Leonardo Lattanzio; Luigi T Marsella; Adriano Tagliabracci; Jeremy Carlier; Francesco P Busardò
Journal:  Metabolites       Date:  2022-07-29

5.  New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study.

Authors:  Yusuf Ali Altuncı; Melike Aydoğdu; Eda Açıkgöz; Ümmü Güven; Fahriye Düzağaç; Aslı Atasoy; Nebile Dağlıoğlu; Serap Annette Akgür
Journal:  Balkan Med J       Date:  2021-01       Impact factor: 2.021

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.